WMSA
PBYI icon

Weiss Multi-Strategy Advisers’s Puma Biotechnology PBYI Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-9,000
Closed -$335K – 617
2017
Q1 		$335K Buy
+9,000
New +$328K 0.01% 500

Other funds holding PBYI

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Weiss Multi-Strategy Advisers's PBYI Position: Q2 2017 in Review

Weiss Multi-Strategy Advisers sold out of Puma Biotechnology (PBYI) in Q2 2017, closing a stake of 9,000 shares — an estimated $335K sold.

Weiss Multi-Strategy Advisers first reported a position in PBYI in Q1 2017 and held it in 1 quarter. The position peaked at $335K in Q1 2017. 154 funds tracked by Wall St. Rank hold PBYI as of Q2 2017.

  • Weiss Multi-Strategy Advisers reported no remaining Puma Biotechnology position as of Q2 2017 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 9,000 Puma Biotechnology shares in Q2 2017, an estimated $335K.
  • Weiss Multi-Strategy Advisers first reported a position in Puma Biotechnology in Q1 2017 and held it in 1 quarter.
  • Weiss Multi-Strategy Advisers's Puma Biotechnology position peaked at $335K in Q1 2017.
  • 154 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2017.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q2 2017, filed 14 Aug 2017.